SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-095187
Filing Date
2022-04-04
Accepted
2022-04-04 16:57:37
Documents
14
Period of Report
2022-04-01
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d329897d8k.htm   iXBRL 8-K 29335
2 EX-16.1 d329897dex161.htm EX-16.1 1838
6 GRAPHIC g329897g0324061931086.jpg GRAPHIC 3956
  Complete submission text file 0001193125-22-095187.txt   156977

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rprx-20220401.xsd EX-101.SCH 2863
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rprx-20220401_lab.xml EX-101.LAB 17236
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rprx-20220401_pre.xml EX-101.PRE 10817
8 EXTRACTED XBRL INSTANCE DOCUMENT d329897d8k_htm.xml XML 3450
Mailing Address 110 EAST 59TH STREET NEW YORK NY 10022
Business Address 110 EAST 59TH STREET NEW YORK NY 10022 (212) 883-0200
Royalty Pharma plc (Filer) CIK: 0001802768 (see all company filings)

IRS No.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39329 | Film No.: 22803329
SIC: 2834 Pharmaceutical Preparations